‘We are very happy to talk about these data with the medical community. The outcomes show that pralatrexate, a novel targeted antifolate designed to accumulate preferentially in cancer cells, achieved long lasting responses, including total responses, in individuals with relapsed or refractory peripheral T-cell lymphoma,’ stated Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. ‘We believe pralatrexate has the potential to give a fresh treatment option for individuals with this devastating disease for which there are currently no approved agents.The adverse aftereffect of enrolling fewer sufferers than prepared was offset by the higher-than-anticipated price of graft failing partially, in a way that the statistical power of the scholarly study was maintained. However, the smaller-than-planned band of individuals may limit the applicability of the subgroup analyses. In addition, because the scholarly study medication was stopped following the primary final result was reached, the possible good thing about continued treatment with aspirin plus dipyridamole on cumulative graft patency could not be evaluated.